Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

We examined effects of carfilzomib-dexamethasone (Kd56) versus bortezomib-dexamethasone (Vd) on health-related quality of life (HR-QoL) in relapsed/refractory multiple myeloma (MM) patients from the ENDEAVOR study. HR-QoL was assessed by the European Organisation for Research and Treatment of Cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Ludwig, Heinz, Moreau, Philippe, Dimopoulos, Meletios A., Mateos, Maria-Victoria, Kaiser, Martin, Hajek, Roman, Feng, Shibao, Cocks, Kim, Buchanan, Jaqueline, Weisel, Katja
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6386751/
https://ncbi.nlm.nih.gov/pubmed/30796199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-019-0181-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados